<p>This full educational program can be accessed at no cost here: <a href="https://annenberg.net/courses/landingPage.php?courseID=61030" target="_blank" rel="ugc noopener noreferrer">https://annenberg.net/courses/landingPage.php?courseID=61030</a></p>

This full educational program can be accessed at no cost here: https://annenberg.net/courses/landingPage.php?courseID=61030

<p>This full educational program can be accessed at no cost here: <a href="https://annenberg.net/courses/landingPage.php?courseID=61030" rel="noopener noreferrer">https://annenberg.net/courses/landingPage.php?courseID=61030</a></p>

Introduction and Key Takeaways

Greater understanding and implementation of molecular biomarkers in non-small cell lung cancer (NSCLC) have led to improved patient outcomes. However, optimizing therapeutic strategies for patients with a molecular alteration continues to be challenging for the multidisciplinary team. Among these alterations, ROS1 rearrangements are rare, but have important clinical implications.

Share Optimizing Treatment in Patients with ROS1 Rearranged NSCLC

Sign up to save your podcasts

Optimizing Treatment in Patients with ROS1 Rearranged NSCLC

FAQs about Optimizing Treatment in Patients with ROS1 Rearranged NSCLC:

How many episodes does Optimizing Treatment in Patients with ROS1 Rearranged NSCLC have?

Optimizing Treatment in Patients with ROS1 Rearranged NSCLC episodes:

FAQs about Optimizing Treatment in Patients with ROS1 Rearranged NSCLC:

How many episodes does Optimizing Treatment in Patients with ROS1 Rearranged NSCLC have?